JACK SU to Child, Preschool
This is a "connection" page, showing publications JACK SU has written about Child, Preschool.
Connection Strength
0.287
-
A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma. Pediatr Blood Cancer. 2020 06; 67(6):e28283.
Score: 0.058
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
Score: 0.020
-
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study. Lancet Oncol. 2024 May; 25(5):668-682.
Score: 0.019
-
Early radiotherapy preserves vision in sporadic optic pathway glioma. Cancer. 2021 07 01; 127(13):2358-2367.
Score: 0.015
-
Neogenin is highly expressed in diffuse intrinsic pontine glioma and influences tumor invasion. Brain Res. 2021 07 01; 1762:147348.
Score: 0.015
-
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol. 2021 03 01; 39(7):822-835.
Score: 0.015
-
Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy. Neuro Oncol. 2019 05 06; 21(5):686-695.
Score: 0.013
-
Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy. Radiother Oncol. 2018 07; 128(1):128-132.
Score: 0.012
-
Patient and treatment factors associated with survival among pediatric glioblastoma patients: A Surveillance, Epidemiology, and End Results study. J Clin Neurosci. 2018 Jan; 47:285-293.
Score: 0.012
-
A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer. 2018 Feb; 65(2).
Score: 0.012
-
Long-term disease control and toxicity outcomes following surgery and intensity modulated radiation therapy (IMRT) in pediatric craniopharyngioma. Radiother Oncol. 2015 Feb; 114(2):224-9.
Score: 0.010
-
A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2015 Feb; 17(2):303-11.
Score: 0.010
-
Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas. J Neurooncol. 2014 Nov; 120(2):293-301.
Score: 0.010
-
Intensity-modulated radiotherapy (IMRT) in pediatric low-grade glioma. Cancer. 2013 Jul 15; 119(14):2654-9.
Score: 0.009
-
Long-term outcome of centrally located low-grade glioma in children. Cancer. 2013 Jul 15; 119(14):2630-8.
Score: 0.009
-
A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study. Pediatr Blood Cancer. 2013 Apr; 60(4):627-32.
Score: 0.009
-
Constitutional tandem duplication of 9q34 that truncates EHMT1 in a child with ganglioglioma. Pediatr Blood Cancer. 2012 May; 58(5):801-5.
Score: 0.008
-
Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. Cancer. 2011 Feb 01; 117(3):635-41.
Score: 0.007
-
Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1445-50.
Score: 0.007
-
Changes mimicking new leptomeningeal disease after intensity-modulated radiotherapy for medulloblastoma. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):214-21.
Score: 0.006
-
Differential expression of survivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol. 2007 Feb; 33(1):67-76.
Score: 0.006
-
Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Cancer Res. 2005 Jan 01; 65(1):76-84.
Score: 0.005